Inclusion criteria
Patients >18 years of age undergoing allogeneic liver transplantation from a cadaveric donor
Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Written informed consent prior to any study procedures
Exclusion criteria
Known allergies to bovine or porcine products
Patients older than 65 years of age
Patients listed in a high-urgency status that would not allow proper preparation of the study interventions
Patients receiving a secondary liver graft (retransplantation)
Double organ transplant recipients
Pre-existing renal failure that requires or has required hemodialysis within the last year
Pulmonary function: FEV1, FVC, DLCO ≤50% predicted
Cardiac function: left ventricular ejection fraction ≤50%
HIV seropositive, HTLV seropositive, varicella virus active infection, or syphilis active infection.
History of any malignancy (including lymphoproliferative disease and hepatocellular carcinoma) except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence
Unstable myocardium (evolving myocardial infarction), cardiogenic shock
Females capable of childbearing (hormonal status and gynecological consultation required)
Males not agreeing to use contraception for the duration of the study
Patient is pregnant, has a positive serum β-hCG, or is lactating
Known current substance abuse (drug or alcohol)
Prisoner
Use of an investigational agent within 30 days prior enrolment
Concurrent enrolment in any other clinical trial
Any psychiatric, addictive or other disorder that compromises ability to give informed consent